Literature DB >> 19007818

Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope.

Wan-Shoo Cheong1, Jessica Reiseger, Stephen John Turner, Richard Boyd, Hans-Jürgen Netter.   

Abstract

The small hepatitis B virus surface antigens (HBsAg-S) have the ability to self-assemble with host-derived lipids into empty non-infectious virus-like particles (VLPs). HBsAg-S VLPs are the sole component of the licensed hepatitis B vaccine, and they are a useful delivery platform for foreign epitopes. To develop VLPs capable of transporting foreign cytotoxic T lymphocyte (CTL) epitopes, HBsAg-S specific CTL epitopes at various sites were substituted with a conserved CTL epitope derived from the influenza matrix protein. Depending on the insertion site, the introduction of the MHC class I A2.1-restricted influenza epitope was compatible with the secretion competence of HBsAg-S indicating that chimeric VLPs were assembled. Immunizations of transgenic HHDII mice with chimeric VLPs induced anti-influenza CTL responses proving that the inserted foreign epitope can be correctly processed and cross-presented. Chimeric VLPs in the absence of adjuvant were able to induce memory T cell responses, which could be recalled by influenza virus infections in the mouse model system. The ability of chimeric HBsAg-S VLPs to induce anti-foreign CTL responses and also with the proven ability to induce humoral immune responses constitute a highly versatile platform for the delivery of selected multiple epitopes to target disease associated infectious agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19007818     DOI: 10.1016/j.antiviral.2008.10.003

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model.

Authors:  Michael Kotiw; Megan Johnson; Manisha Pandey; Scott Fry; Stuart L Hazell; Hans J Netter; Michael F Good; Colleen Olive
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

Review 2.  Virus-Based Nanoparticles as Versatile Nanomachines.

Authors:  Kristopher J Koudelka; Andrzej S Pitek; Marianne Manchester; Nicole F Steinmetz
Journal:  Annu Rev Virol       Date:  2015-09-25       Impact factor: 10.431

3.  Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.

Authors:  Michiko Hyakumura; Renae Walsh; Morten Thaysen-Andersen; Natalie J Kingston; Mylinh La; Louis Lu; George Lovrecz; Nicolle H Packer; Stephen Locarnini; Hans J Netter
Journal:  J Virol       Date:  2015-09-02       Impact factor: 5.103

Review 4.  Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.

Authors:  Zuzana Staneková; Eva Varečková
Journal:  Virol J       Date:  2010-11-30       Impact factor: 4.099

Review 5.  Engineered biological entities for drug delivery and gene therapy protein nanoparticles.

Authors:  Joan Domingo-Espín; Ugutz Unzueta; Paolo Saccardo; Escarlata Rodríguez-Carmona; José Luís Corchero; Esther Vázquez; Neus Ferrer-Miralles
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

6.  Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus.

Authors:  Anna Czarnota; Jolanta Tyborowska; Grażyna Peszyńska-Sularz; Beata Gromadzka; Krystyna Bieńkowska-Szewczyk; Katarzyna Grzyb
Journal:  Microb Cell Fact       Date:  2016-04-13       Impact factor: 5.328

7.  Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency.

Authors:  Anna Czarnota; Anna Offersgaard; Anne Finne Pihl; Jannick Prentoe; Jens Bukh; Judith Margarete Gottwein; Krystyna Bieńkowska-Szewczyk; Katarzyna Grzyb
Journal:  Vaccines (Basel)       Date:  2020-06-10

Review 8.  Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.

Authors:  Joan Kha-Tu Ho; Beena Jeevan-Raj; Hans-Jürgen Netter
Journal:  Viruses       Date:  2020-01-21       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.